View profile

FarmaKology-Mutations in SARS-CoV-2 Omicron variant promote cell binding



January 18 · Issue #92 · View online

FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to, and happy to have you featured on our newsletter (+13K Subscribers )!

Novo Banking
Novo Banking
Today's Company
Vir Biotechnology
Vir Biotechnology
Vir Biotechnology
Vir Biotechnology brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. Vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. The company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
Neurimmune AG today announced that it has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. The collaboration is focused on creating antibody drugs against new therapeutic targets in the field of neurodegenerative diseases utilizing Neurimmune’s proprietary Reverse Translational Medicine™ (RTM™) technology platform, a unique antibody drug creation approach.
Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, today announces that it has agreed to acquire the Canadian assets of Teligent Inc. for $45.75 million. The transaction is expected to be completed before the end of the first quarter of 2022.
Revive Therapeutics Ltd., a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s psilocybin pharmaceutical development programs.
Australia’s competition regulator on Monday said it had “significant concerns” about reports of price gouging of COVID-19 rapid antigen tests and sought information from suppliers, retailers and pharmacy chains about rising costs. Australia is facing a shortage of at-home rapid antigen test kits after authorities urged asymptomatic close contacts to bypass government-funded testing hubs, where high volumes delayed results, and take their own tests.
Research & Study
Stream Episode 115 - Why a MD Think Pharmacists Should Prescriber for COVID with Dr. Richard Harris by Political Pharmacist | Listen online for free on SoundCloud
Job Opportunities
Upcoming Webinar
Coronavirus and the money behind vaccines | FT Film
Did you enjoy this issue?
In order to unsubscribe, click here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue